Staidson (300204.SZ) announced its semi-annual report for 2024, with a revenue of 0.182 billion yuan, a year-on-year growth of 7.69%; net income attributable to shareholders of the listed company was -3.423 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -6.374 million yuan; basic earnings per share was -0.01 yuan.
During the reporting period, Staidson achieved sales revenue of 98.99 million yuan, accounting for 54.27% of the revenue, a year-on-year increase of 20.06%; Sutaisin achieved sales revenue of 78.82 million yuan, accounting for 43.21% of the revenue, a year-on-year decrease of 5.71%; Aspirin enteric-coated tablets contributed sales revenue of 1.83 million yuan.